Articles by Michelle Hoffman - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Michelle Hoffman

Coming Down the Pike: Endocannabinoids

Scientists are uncovering signaling systems that operate via cannabinoid messenger molecules.
Jun 2, 2008

Scientists are uncovering signaling systems that operate via cannabinoid messenger molecules.

Cell Manufacturing on a Large Scale

Creating a kinder, gentler manufacturing process that doesn't kill the product is the goal of process developers doing large-scale cell culture for cell therapy.
Jun 2, 2008

Creating a kinder, gentler manufacturing process that doesn't kill the product is the goal of process developers doing large-scale cell culture for cell therapy.

Requiem for a Vaccine

Scientists are giving up on a preventive vaccine for AIDS, but there are lessons to be learned.
May 2, 2008

Scientists are giving up on a preventive vaccine for AIDS, but there are lessons to be learned.

Coming Down the Pike: Bispecific mABs

Apr 2, 2008

Antibodies are highly specific molecules that can be tailored to recognize almost any stretch of peptide that nature can conjure: a feature that has been exploited for years now to produce therapeutic antibodies.

Message in a Bottle

The FDA itself issues a cry for help. Is anybody listening?
Apr 2, 2008

The FDA itself issues a cry for help. Is anybody listening?

Coming Down the Pike: HDAC inhibitors

Mar 2, 2008

New research and ideas for March 2008

Coming Down the Pike: Sirtuins

Feb 2, 2008

Text sirtuins are the new kinases, according to a presentation given last month at the JP Healthcare Investors Conference in San Francisco by Sirtis CEO Christoph Westphal.

Patents "R" Us

Can an overload of patent applications lead to the US' demise as a scientific leader?
Feb 2, 2008

Can an overload of patent applications lead to the US' demise as a scientific leader?

Candidate Copout

Fixing FDA lies in the hands of the government, but is the president-to-be paying attention?
Jan 2, 2008

Fixing FDA lies in the hands of the government, but is the president-to-be paying attention?

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here